Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Johnson & Johnson (JNJ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM ESTCompany ParticipantsCandice Long - Worldwide ...
The Malaysian Reserve

New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving ...